CSL Limited
CSL
Rangering i aksjer
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aksjekurs
$138.33
Markedsverdi
$66.38B
Endring (1 dag)
-0.22%
Endring (1 år)
-3.31%
Land
AU
Handel CSL Limited (CSL)
Kategori
Healthcare
Historikk for aksjesplitt for CSL Limited (CSL)
Aksjen CSL Limited (symbol: CSL) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Oct 18, 2007.
Én CSL-aksje kjøpt før Oct 18, 2007 tilsvarer i dag 3 CSL-aksjer.
Den nyeste splittelsen skjedde Oct 18, 2007.
Én CSL-aksje kjøpt før Oct 18, 2007 tilsvarer i dag 3 CSL-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2007-10-18 | 3:1 | x3 | x3 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
|
| 1 | x100 |
BE
|
